OBJECTIVES: To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome. DESIGN AND METHODS: A new sandwich ELISA was introduced and clinically tested. RESULTS: ZAG serum level did not differentiate healthy subjects (27.4+/-8.3 mg/L; N=132) from patients with metabolic syndrome (24.9+/-8.1; N=92). ZAG correlated with glucose, creatinine and uric acid. CONCLUSION: The immunoassay offers a new research tool for glucose metabolism.
OBJECTIVES: To develop an assay for the determination of ZAG in human serum, and to investigate its clinical relevance as a marker of metabolic syndrome. DESIGN AND METHODS: A new sandwich ELISA was introduced and clinically tested. RESULTS:ZAG serum level did not differentiate healthy subjects (27.4+/-8.3 mg/L; N=132) from patients with metabolic syndrome (24.9+/-8.1; N=92). ZAG correlated with glucose, creatinine and uric acid. CONCLUSION: The immunoassay offers a new research tool for glucose metabolism.
Authors: Sidgi Syed Anwer Hasson; Mohammed Saeed Al-Balushi; Muzna Hamed Al Yahmadi; Juma Zaid Al-Busaidi; Elias Antony Said; Mohammed Shafeeq Othman; Talal Abdullah Sallam; Mohammed Ahmad Idris; Ali Abdullah Al-Jabri Journal: Asian Pac J Trop Biomed Date: 2014-08
Authors: H Stepan; A Philipp; I Roth; S Kralisch; A Jank; W Schaarschmidt; U Lössner; J Kratzsch; M Blüher; M Stumvoll; M Fasshauer Journal: J Endocrinol Invest Date: 2011-07-27 Impact factor: 4.256
Authors: Lourdes Garrido-Sánchez; Eduardo García-Fuentes; Diego Fernández-García; Xavier Escoté; Juan Alcaide; Pablo Perez-Martinez; Joan Vendrell; Francisco J Tinahones Journal: PLoS One Date: 2012-03-19 Impact factor: 3.240